Evicenter
P&T meetings

Juvmo (tavapadon)

Parkinson's disease

Also known as CVL-751
Manufacturer
AbbVie
Regulatory submission
NDA submitted September 2025
Last updated
217 sources

Product information and disease descriptionProduct descriptionProduct informationDrug/Drug, drug/disease interactions

Effects of other drugs on tavapadon

9 evidence topics · 3 sources

CYP3A inhibitors and inducers: prescribing information summary

“Avoid concomitant use of strong or moderate CYP3A inhibitors during titration and strong CYP3A inducers during titration and maintenance of JUVMO. (2.2, 7.1)” (opens the prescribing information at this quote)

“Strong and moderate CYP3A inhibitors: Decrease dosing frequency. (2.2, 7.1)” (opens the prescribing information at this quote)

“Strong CYP3A inducers: Concomitant use is not recommended. (2.3, 7.1)” (opens the prescribing information at this quote)

“Moderate CYP3A inducers (long-term): Increase dosing frequency. (2.3, 7.1)” (opens the prescribing information at this quote)

Strong and moderate CYP3A inhibitors: mechanism and clinical effect

“Tavapadon is CYP3A substrate. Concomitant use of strong and moderate CYP3A inhibitors increase the exposure of tavapadon, which may increase the risk of adverse reactions [see Clinical Pharmacology (12.3)].” (opens the prescribing information at this quote)

“Concomitant use of strong CYP3A inhibitors may increase the risk of hallucinations [see Warnings and Precautions (5.3), Clinical Pharmacology (12.3)].” (opens the prescribing information at this quote)

Strong CYP3A inhibitor: itraconazole

“Concomitant administration of itraconazole (200 mg daily for 14 days), a strong CYP3A inhibitor, with JUVMO increased tavapadon AUCτ and Cmax by 5-fold and 4-fold, respectively.” (opens the prescribing information at this quote)

“The purpose of this study is to evaluate the impact of CYP3A4 inhibitor, itraconazole, on plasma concentration of PF-06649751 in healthy subjects” (opens the source at this quote in a new tab)

Moderate CYP3A inhibitor: fluconazole (model-predicted)

“Concomitant administration of fluconazole (200 mg daily), a moderate CYP3A inhibitor, with 15 mg JUVMO at steady-state is predicted to increase the AUCτ and Cmax of tavapadon by approximately 2.6-fold and 2.3-fold, respectively.” (opens the prescribing information at this quote)

Strong and moderate CYP3A inducers: mechanism and clinical effect

“Tavapadon is CYP3A substrate. Concomitant use of strong or moderate CYP3A inducer decreases the exposure of tavapadon which may result in reduced JUVMO efficacy [see Clinical Pharmacology (12.3)].” (opens the prescribing information at this quote)

Strong CYP3A inducer: carbamazepine

“Concomitant administration of carbamazepine (300 mg twice daily), a strong CYP3A inducer, with JUVMO decreased tavapadon AUCτ and Cmax by 63% and 49%, respectively [see Dosage and Administration (2.3), Drug Interactions (7.1)].” (opens the prescribing information at this quote)

“The primary purpose of this study is to evaluate the effect of carbamazepine, a strong CYP3A4 inducer, on the steady-state pharmacokinetics (PK) of tavapadon in healthy adult participants.” (opens the source at this quote in a new tab)

Moderate CYP3A inducer: efavirenz (model-predicted)

“Concomitant administration of efavirenz (600 mg), a moderate CYP3A inducer, with 15 mg JUVMO is predicted to decrease the AUCτ and Cmax of tavapadon by 70% and 58%, respectively.” (opens the prescribing information at this quote)

In vitro substrate profile for enzymes and transporters

“Cytochrome P450 (CYP450) Enzymes: Tavapadon and M4 are substrates of CYP3A, but are not substrates of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2D6.” (opens the prescribing information at this quote)

“Transporter Systems: Tavapadon is a substrate for P-gp and BCRP, but is not expected to result in clinically significant drug interactions.” (opens the prescribing information at this quote)

Counseling on herbal products and changes in concomitant medications

“Advise patients and/or caregivers to inform their healthcare provider of all the medicines the patient is taking, including over-the-counter medicines, dietary supplements, and herbal products (e.g., St. John’s Wort), and if there is a change (e.g., discontinuing) in their medication [see Dosage and Administration (2.2, 2.3), Drug Interactions (7.1, 7.2)].” (opens the prescribing information at this quote)